Updating Treatments for Fecal Incontinence V

1. What is the decision or change you are facing or struggling with where a summary of the evidence would be helpful?

I recommend updating the 3/21/16 systematic review entitled "Treatments of Fecal Incontinence". It needs to include the data from the myriad of studies that have been published since this report. Specifically as they pertain to Solesta which has been approved by the FDA.

2. Why are you struggling with this issue?

Recent studies demonstrate long-term efficacy, safety, and durability of Solesta.

3. What do you want to see changed? How will you know that your issue is improving or has been addressed?

I would like to see inclusion of all existing studies including: Mellgren et al., 2014: Reports of long-term efficacy of Solesta Franklin et al., 2016: Benefit of Solesta over Sham Recommendation of Solesta as separate and distinct from other bulking agents.

4. When do you need the evidence report?

Monday, March 15, 2021

5. What will you do with the evidence report?

These updated guidelines will be used to educate physicians, patients and third party payers. Presently over 8% of non-institutionalized adults suffer FI. There is approximately 11 billion dollars spent annually and nursing home referrals are increased 10–15% because of FI.

(Optional) About You

What is your role or perspective? Physician

May we contact you if we have questions about your nomination? Yes

Title: MD